Literature DB >> 12614220

Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase.

Keichiro Mihara1, Chihaya Imai, Elaine Coustan-Smith, Jeffrey S Dome, Massimo Dominici, Elio Vanin, Dario Campana.   

Abstract

To create immortal mesenchymal cell lines, we transduced primary human bone marrow mesenchymal cells with telomerase reverse transcriptase (TERT). TERT+ mesenchymal cells continued to grow for > 2 years; parallel TERT- cultures underwent senescence after 15 weeks. TERT+ mesenchymal cells did not form foci in soft agar, had a normal karyotype and could differentiate into osteoblasts and chondrocytes. Their capacity to support leukaemic lymphoblasts and normal CD34+ haematopoietic cells was equal to or greater than that of primary cells; 42 TERT+ mesenchymal cell clones varied in their supporting capacity. Immortalized mesenchymal cells offer a promising tool for identifying molecules that regulate human haematopoiesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614220     DOI: 10.1046/j.1365-2141.2003.04217.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  51 in total

1.  Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth.

Authors:  Sabine Pfeifer; Martin Schreder; Arnold Bolomsky; Sebastian Graffi; Dietmar Fuchs; Surinder S Sahota; Heinz Ludwig; Niklas Zojer
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-22       Impact factor: 4.553

2.  A shorter telomere is the key factor in preventing cultured human mesenchymal stem cells from senescence escape.

Authors:  Liu He; Yong Zheng; Yu Wan; Jian Song
Journal:  Histochem Cell Biol       Date:  2014-09       Impact factor: 4.304

3.  Identification of genes regulated by the EWS/NR4A3 fusion protein in extraskeletal myxoid chondrosarcoma.

Authors:  Christine Filion; Yves Labelle
Journal:  Tumour Biol       Date:  2012-05-18

4.  BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

Authors:  Victoria Del Gaizo Moore; Krysta D Schlis; Stephen E Sallan; Scott A Armstrong; Anthony Letai
Journal:  Blood       Date:  2007-12-04       Impact factor: 22.113

5.  Osteoblasts protect AML cells from SDF-1-induced apoptosis.

Authors:  Kimberly N Kremer; Amel Dudakovic; Meghan E McGee-Lawrence; Rachael L Philips; Allan D Hess; B Douglas Smith; Andre J van Wijnen; Judith E Karp; Scott H Kaufmann; Jennifer J Westendorf; Karen E Hedin
Journal:  J Cell Biochem       Date:  2014-06       Impact factor: 4.429

6.  Generation and characterization of an immortalized human mesenchymal stromal cell line.

Authors:  Magne Skårn; Paul Noordhuis; Meng-Yu Wang; Marjan Veuger; Stine Henrichson Kresse; Eivind Valen Egeland; Francesca Micci; Heidi Maria Namløs; Anne-Mari Håkelien; Solveig Mjelstad Olafsrud; Susanne Lorenz; Guttorm Haraldsen; Gunnar Kvalheim; Leonardo Andrés Meza-Zepeda; Ola Myklebost
Journal:  Stem Cells Dev       Date:  2014-06-30       Impact factor: 3.272

7.  Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.

Authors:  Bin Zhang; Min Li; Tinisha McDonald; Tessa L Holyoake; Randall T Moon; Dario Campana; Leonard Shultz; Ravi Bhatia
Journal:  Blood       Date:  2013-01-08       Impact factor: 22.113

8.  CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.

Authors:  Michael N Dworzak; Angela Schumich; Dieter Printz; Ulrike Pötschger; Zvenyslava Husak; Andishe Attarbaschi; Giuseppe Basso; Giuseppe Gaipa; Richard Ratei; Georg Mann; Helmut Gadner
Journal:  Blood       Date:  2008-09-09       Impact factor: 22.113

9.  Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.

Authors:  J G Harb; P Neviani; B J Chyla; J J Ellis; G J Ferenchak; J J Oaks; C J Walker; P Hokland; D C Roy; M A Caligiuri; G Marcucci; C S Huettner; D Perrotti
Journal:  Leukemia       Date:  2013-05-14       Impact factor: 11.528

10.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.

Authors:  Hiroyuki Fujisaki; Harumi Kakuda; Noriko Shimasaki; Chihaya Imai; Jing Ma; Timothy Lockey; Paul Eldridge; Wing H Leung; Dario Campana
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.